Focused On-demand Library for Potassium voltage-gated channel subfamily H member 1

Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We use our state-of-the-art dedicated workflow for designing focused libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

PARTNER
Receptor.AI
 
UPACC
O95259

UPID:
KCNH1_HUMAN

ALTERNATIVE NAMES:
Ether-a-go-go potassium channel 1; Voltage-gated potassium channel subunit Kv10.1

ALTERNATIVE UPACC:
O95259; B1AQ26; O76035; Q14CL3

BACKGROUND:
The protein Potassium voltage-gated channel subfamily H member 1, with aliases Ether-a-go-go potassium channel 1 and Kv10.1, is integral to cellular electrical stability and signaling. It forms the alpha subunit of a voltage-gated potassium channel, modulating cell membrane potential and influencing key cellular processes such as proliferation and differentiation, especially in bone marrow-derived mesenchymal stem cells.

THERAPEUTIC SIGNIFICANCE:
The association of this protein with Temple-Baraitser syndrome and Zimmermann-Laband syndrome 1, characterized by intellectual disability and developmental defects, underscores its potential as a target for therapeutic intervention. Exploring the function of Potassium voltage-gated channel subfamily H member 1 could lead to breakthroughs in treating these genetic disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.


Page 103 of 8789